Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[177Lu]Lu-AKIR001 in Advanced CD44v6-Expressing Solid Tumors
NCT06639191Phase 1Recruiting
- Sponsor
- Karolinska University Hospital
- Start
- Jan 2026
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lutetium-177 AKIR001 in anaplastic thyroid carcinoma (ATC), poorly differentiated thyroid carcinoma (PDTC), head and neck squamous cell carcinoma (HNSCC) and 3 more, sponsored by Karolinska University Hospital. Primary endpoint: Dose Limiting Toxicities at 6 weeks. Started Jan 2026; status: recruiting.
02
Drugs
lutetium-177 AKIR001
03
Conditions
anaplastic thyroid carcinoma (ATC)poorly differentiated thyroid carcinoma (PDTC)head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)vulvar squamous cell carcinoma (VSCC)
Beyond the preview
Go deeper on NCT06639191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06639191.